Clinical Trial Detail

NCT ID NCT02657889
Title Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Tesaro, Inc.
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

triple-receptor negative breast cancer

Therapies

Niraparib + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.